Table 1.
Characteristics of CVID patients by type of immunoglobulin treatment at T1
| fSCIG n = 33 |
SCIG n = 59 |
IVIG n = 206 |
SCIG + IVIG n = 6 |
|
|---|---|---|---|---|
| Age (years), mean (SD) | 40.3 (11.2)c | 45.2 (13.1) | 49.2 (16.1)a | 39.2 (13.1) |
| Sex (females), n (%) | 11.5(33.1) | 26.1 (44.2) | 113.2 (55.2) | 4.5 (67.2) |
| Occupation (employed), n (%) | 25 (75) | 34 (57) | 99 (48) | 3 (50) |
| Education (≥ high school), n (%) | 30 (90) | 48 (81) | 150 (73) | 5 (83) |
| Time (years) from PID diagnosis, mean (SD) | 11.2 (9.2) | 9.0 (7.1)d | 12.3 (11.1) | 19.1 (11.0)b |
| Ig serum levels at diagnosis: | ||||
| - IgG (mg/dL), mean (SD) | 326.3 (183.5) | 313.3 (161.2) | 246.5 (179.2) | 160.2 (186.3) |
| - IgM (mg/dL), mean (SD) | 23.2 (21.2) | 27.2 (24.6) | 26.1 (38.6) | 5.2 (5.1) |
| - IgA (mg/dL), mean (SD) | 39.1 (52.3) | 28.2 (33.5) | 22.3 (58.3) | 18.2 (26.2) |
| IgG trough serum levels (mg/dL), mean (SD) | 713.3 (115.1) | 745.0 (109.2)d | 725.1 (180.2) | 600.5 (122.3)b |
| CD3+ CD4+/mm3, mean (SD) | 785.3 (542.1) | 740 (381) | 624.1 (343.2) | 935.7 (763.1) |
| CD19+ (%), mean (SD) | 8.6 (8.3) | 12 (17) | 13.1 (23.2) | 6.1 (1.0) |
| CD19+ CD27+ IgM− IgD− (%), mean (SD) | 7.8 (14.7) | 7 (10) | 6.1 (14.2) | 2.1 (3.2) |
ap < 0.01 in comparison to fSCIG group
bp < 0.01 in comparison to SCIG group
cp < 0.01 in comparison to IVIG group
dp < 0.01 in comparison to IVIG + SCIG group